New trial
Phase I 8R-70CAR T cells: IL-8 receptor modified CD70-targeted immunotherapy
- Trial ID
- NCT05353530 on ClinicalTrials.gov
- Cancer type
- Glioblastoma
- Published in
- New in Oncology - June 16, 2025
A Phase I trial evaluating safety and feasibility of ex-vivo expanded autologous IL-8 receptor-modified CD70 CAR T cell therapy in patients with CD70+ adult glioblastoma and pediatric high-grade gliomas. Sponsored by the University of Florida, the study seeks to determine optimal dosing and potential early efficacy signals for this experimental immunotherapy strategy.
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma